文献速递哮喘

母亲17q21基因型影响产前维生素D对子代哮喘/反复喘息的作用

Maternal 17q21 genotype influences prenatal vitamin D effects on offspring asthma/recurrent wheeze.
PubMed 文献 · Eur Respir J · 2021-09-23

基于VDAART(n=613)和COPSAC2010(n=563)两项随机对照试验,分析母亲rs12936231基因型对产前高剂量维生素D3补充预防子代0-3岁哮喘/反复喘息效果的影响。母亲为低风险GG或GC基因型时,补充组子代风险显著降低;母亲为高风险CC基因型时未见差异。

要点

  • 母亲rs12936231低风险GG/GC基因型者,产前高剂量维生素D3可降低子代哮喘/反复喘息风险。
  • 母亲为高风险CC基因型者,产前维生素D3补充未见保护作用。
  • 母亲17q21基因型可能影响产前维生素D3补充的个体化获益。

核心结论

  • 母亲17q21基因型对产前维生素D3补充预防子代哮喘/反复喘息的保护效应有重要影响。

研究设计与样本

  • 研究基于两项随机对照试验:VDAART(n=613)和COPSAC2010(n=563),测定母子对的rs12936231基因型。
  • 比较产前高剂量维生素D3补充组与安慰剂组子代0-3岁哮喘/反复喘息的发生风险。

主要发现

  • 母亲为低风险GG或GC基因型时,补充组子代哮喘/反复喘息风险显著降低:VDAART HR 0.54(95%CI 0.37-0.77;p<0.001),COPSAC2010 HR 0.56(95%CI 0.35-0.92;p=0.021)。
  • 母亲为高风险CC基因型时,补充组与安慰剂组无差异:VDAART HR 1.05(95%CI 0.61-1.84;p=0.853),COPSAC2010 HR 1.11(95%CI 0.54-2.28;p=0.785)。

临床怎么用

  • 对于母亲携带rs12936231低风险GG/GC基因型的子代,产前维生素D3补充可能降低早期哮喘/反复喘息风险。
  • 母亲为高风险CC基因型时,产前维生素D3补充的获益不明确,需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prenatal vitamin D3 supplementation has been linked to reduced risk of early-life asthma/recurrent wheeze. This protective effect appears to be influenced by variations in the 17q21 functional single nucleotide polymorphism rs12936231 of the child, which regulates the expression of ORMDL3 (ORM1-like 3) and for which the high-risk CC genotype is associated with early-onset asthma. However, this does not fully explain the differential effects of supplementation. We investigated the influence of maternal rs12936231 genotype variation on the protective effect of prenatal vitamin D3 supplementation against offspring asthma/recurrent wheeze. METHODS: We determined the rs12936231 genotype of mother-child pairs from two randomised controlled trials: the Vitamin D Antenatal Asthma Reduction Trial (VDAART, n=613) and the Copenhagen Prospective Studies on Asthma in Childhood 2010 (COPSAC2010, n=563), to examine the effect of maternal genotype variation on offspring asthma/recurrent wheeze at age 0-3 years between groups who received high-dose prenatal vitamin D3 supplementation versus placebo. RESULTS: Offspring of mothers with the low-risk GG or GC genotype who received high-dose vitamin D3 supplementation had a significantly reduced risk of asthma/recurrent wheeze when compared with the placebo group (hazard ratio (HR) 0.54, 95% CI 0.37-0.77; p<0.001 for VDAART and HR 0.56, 95% CI 0.35-0.92; p=0.021 for COPSAC2010), whereas no difference was observed among the offspring of mothers with the high-risk CC genotype (HR 1.05, 95% CI 0.61-1.84; p=0.853 for VDAART and HR 1.11, 95% CI 0.54-2.28; p=0.785 for COPSAC2010). CONCLUSION: Maternal 17q21 genotype has an important influence on the protective effects of prenatal vitamin D3 supplementation against offspring asthma/recurrent wheeze.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Knihtilä HM, Kelly RS, Brustad N, et al. Maternal 17q21 genotype influences prenatal vitamin D effects on offspring asthma/recurrent wheeze. Eur Respir J. 2021. PMID: 33653805. doi:10.1183/13993003.02012-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。